Selective agonists of thyroid hormone receptor beta: promising tools for the treatment of nonalcoholic fatty liver disease
As Healio previously reported, the FDA removed tirzepatide (Mounjaro/Zepbound, Eli Lilly) and semaglutide (Ozempic/Wegovy, Novo Nordisk) from its drug shortage list in 2024 and 2025, respectively, and now prohibits both 503A compounding pharmacies and 503B outsourcing facilities from distributing compounded versions of the drug
159 A subset of responders continued the treatments for up to one year, resulting in 40% of patients overall reporting continued relief at the one year point
Adaptations in brain reward circuitry underlie palatable food cravings and anxiety induced by high-fat diet withdrawal
Like, how does that feel
Global Speaker: A trusted voice at over 200 international conferences, including the American College of Sports Medicine, IHRSA, and the American Cancer Society